Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

BMC Cancer
Zhengwu SunYalin Xi

Abstract

It is not known what combination of bevacizumab and chemotherapy agents is the best therapeutic regimen. Comparative study results among the efficacies of bevacizumab plus chemotherapy remain controversial in patients with HER2-negative metastatic breast cancer. We searched Pubmed, Embase, and Cochrane Library Central Resister of Controlled Trials through were July 2019 for randomized controlled trials that evaluated the efficacy of bevacizumab plus chemotherapy in HER2-negative metastatic breast cancer. Data on included study characteristics, outcomes, and risk of bias were abstracted by two reviewers. A total of 16 RCT studies involving 5689 patients were included. The results showed that bevacizumab (Bev) - taxanes (Tax) - capecitabine (Cap) has highest-ranking and is probably more effective for prolonging progression-free survival (PFS) than Tax, Cap, Bev-Tax and Bev-Cap, which was no convincing differences among Bev-Cap-vinorelbine, Bev-Tax-everolimus, Bev-Tax-trebananib, Bev-exemestane, Bev-Cap-cyclophosphamide in Bev-containing regimens. For overall response rate (ORR), Bev-Tax-Cap is superior to Tax, Cap and Bev-Cap, while Bev-Tax-trebananib is superior to Cap. The cumulative probability ranking showed that Bev-Tax-Cap ...Continue Reading

References

Nov 18, 1971·The New England Journal of Medicine·J Folkman
Apr 9, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michel Marty, Xavier Pivot
Jul 4, 2008·Nature Reviews. Cancer·Lee M Ellis, Daniel J Hicklin
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert GrayRobert L Comis
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David W MilesGilles Romieu
Jan 27, 2012·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Jan 27, 2012·The New England Journal of Medicine·Harry D BearNorman Wolmark
Dec 3, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S W LamUNKNOWN Dutch Breast Cancer Research Group
Feb 27, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O TrédanT Bachelot
Nov 8, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David MilesJoyce O'Shaughnessy

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

RevMan
R
GeMTC

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.